Read the emergency medicine commentary on HyperRAB, then complete the CME activity.
Explore This Issue
ACEP Now: Vol 37 – No 09 – September 2018
Dr. Kaufman is a board-certified geriatric pharmacist, a pharmacist at NewYork-Presbyterian/Lower Manhattan Hospital, and a freelance medical writer and editor.
References
- Grifols HyperRAB (rabies immune globulin [human]) 300 IU/mL receives FDA approval to treat patients exposed to rabies virus infection. PR Newswire website. Accessed June 14, 2018.
- Rabies immune globulin (human). Lexicomp Online [database online]. Hudson, OH: Wolters Kluwer Clinical Drug Information. Updated May 23, 2018. Accessed June 14, 2018.
Pages: 1 2 | Single Page
2 Responses to “New, More Potent Rabies Treatment Now Available”
October 19, 2018
Ursula MakkerBe advised HRIG is dosed by body weight. Since younger patients generally weigh less, and the dose (volume) is already small, now having to use half of the previous volume may make adequate infiltration difficult with 300 IU product vs. original 150 IU product. Note: as per the manufacturer, if there is not enough volume of 300 IU product to adequately infiltrate, 300 IU must be diluted with equal volume of 5% Dextrose – for which there is no existing pharmacy SOP. This also negates the double potency/half volume feature. 150 IU remains the ideal and preferred potency for HRIG when treating patients exposed to the deadly rabies virus.
November 8, 2020
Mahmood PeshimamWhat is the insurance reimbursement compared to the cost of RIG
a) 300 IU/ml?
b) 150 IU/ml?